Advanced Bioanalytical Antibodies and IgM-FcSpyCatcher Expand Capabilities for ELISA, Western Blotting, and Drug Monitoring

Bio-Rad Laboratories, a global provider of life science and clinical diagnostics products, has announced the latest additions to its range of bioanalytical antibodies, strengthening its commitment to bioanalysis innovation. The new release includes recombinant monoclonal anti-idiotypic antibodies for five major therapeutics—pertuzumab (Perjeta), guselkumab (Tremfya), canakinumab (Ilaris), belimumab (Benlysta), and the bispecific antibody emicizumab (Hemlibra)—as well as a novel Human IgM-FcSpyCatcher reagent.

These new tools enhance analytical flexibility and assay performance, enabling more precise pharmacokinetic (PK) and anti-drug antibody (ADA) testing for both innovator and biosimilar therapeutics.

Key Features of the New Bioanalytical Antibodies and SpyCatcher Reagent:

• Specificity for five widely used therapeutic antibodies

• Compatibility with ELISA, western blotting, and precipitation assays

• Human IgM-FcSpyCatcher supports fast IgM format switching at the protein level

• Enables pentameric and hexameric IgM formation

• Designed for preclinical, clinical, and in vitro diagnostic workflows

Bio-Rad now offers over 250 anti-biotherapeutic antibodies spanning 45 specificities, ensuring researchers have access to comprehensive and scalable options for assay development.